Evenity and Prolia treat osteoporosis through fundamentally different approaches, and neither is universally “better.” Evenity is a short-term bone builder that actively stimulates new bone growth while also slowing bone loss. Prolia is a long-term maintenance drug that slows bone breakdown but doesn’t build new bone. For many patients, the most effective strategy is using both drugs in sequence: Evenity first, then Prolia afterward.
How Each Drug Works
Prolia (denosumab) is an antiresorptive. It blocks a signal that activates the cells responsible for breaking down bone. With those cells suppressed, your body stops losing bone as quickly. Think of it as hitting the brakes on bone loss. It doesn’t, however, put new bone tissue in place.
Evenity (romosozumab) has a dual mechanism. It blocks a protein called sclerostin, which normally holds back bone-building activity. When sclerostin is blocked, two things happen at once: your bone-forming cells ramp up production, and your bone-resorbing cells slow down. So Evenity works like pressing the gas and the brakes at the same time, rapidly increasing bone density in a way that Prolia alone cannot.
Bone Density Gains Compared
The difference in bone density improvements is significant. In the phase 3 FRAME trial, patients who received 12 months of Evenity followed by Prolia gained an average of 16.6% in spine bone density and 8.5% at the total hip over two years. Those are among the largest bone density gains seen in any osteoporosis treatment sequence studied.
Prolia on its own does increase bone density, but at a slower, steadier pace. It takes years of continuous use to approach the gains that the Evenity-then-Prolia sequence delivers in two years. This is why Evenity is typically positioned as a first-strike treatment for patients at high fracture risk, not a long-term maintenance therapy.
Treatment Duration and Schedule
Evenity is given as two subcutaneous injections once a month, administered by a healthcare provider. The treatment course is strictly limited to 12 months because its bone-building effect fades after that point. You cannot repeat or extend a course of Evenity.
Prolia is given as a single injection every six months, and it’s designed for ongoing, indefinite use. This is partly because of what happens when you stop it. Within 18 months of discontinuing Prolia, patients face a rebound effect where bone loss accelerates rapidly. Some patients, particularly those with a history of vertebral fractures, develop multiple new vertebral fractures in as little as nine months after their last dose. This means once you start Prolia, you need a clear plan for what comes next if you ever stop.
The Case for Using Both in Sequence
Most current treatment strategies for high-risk patients involve starting with Evenity for 12 months, then transitioning directly to Prolia afterward. This approach captures the aggressive bone-building phase of Evenity and then locks in those gains with Prolia’s antiresorptive effect. The data from clinical trials supports this order specifically: Evenity first, then Prolia.
Going the other direction is less effective. When romosozumab is given after denosumab, the spine still gains density, but hip bone density only holds steady rather than increasing. The bone-building signal from Evenity is somewhat blunted if the antiresorptive has already been running. So if you’re currently on Prolia and considering Evenity, it can still help, but the gains won’t be as dramatic as starting with Evenity from the beginning.
Cardiovascular Risk With Evenity
Evenity carries a boxed warning for cardiovascular events. In one clinical trial comparing it to another osteoporosis drug, heart attacks occurred in 0.8% of the Evenity group versus 0.2% of the comparison group. Strokes occurred in 0.6% versus 0.3%. Overall major cardiac events hit 2.0% with Evenity compared to 1.1% in the comparison group. A separate placebo-controlled trial showed no difference (0.8% in both groups), so the picture is somewhat mixed, but the warning remains.
Evenity is contraindicated if you’ve had a heart attack or stroke. For patients with cardiovascular risk factors like high blood pressure, high cholesterol, diabetes, smoking, or kidney disease, the decision requires weighing fracture risk against heart risk. Prolia does not carry this cardiovascular concern, which is one clear advantage it holds.
Who Gets Evenity vs. Prolia
Evenity is generally reserved for postmenopausal women at high risk of fracture, particularly those who haven’t responded well to other osteoporosis treatments or who experienced bothersome side effects from them. It’s the more aggressive option, meant for people whose fracture risk is high enough to justify a potent, time-limited intervention.
Prolia has broader use. It’s prescribed for postmenopausal osteoporosis more generally, as well as for bone loss related to certain cancer treatments. Because it doesn’t carry the cardiovascular warning, it’s an option for patients with heart disease or stroke history who can’t safely take Evenity. It’s also the default long-term maintenance therapy after an Evenity course ends.
Cost Considerations
Both drugs are brand-name biologics, and neither is cheap. Costs depend heavily on your insurance plan, because both are administered by a healthcare provider and may be billed through medical coverage (like Medicare Part B) rather than prescription drug benefits. This billing distinction can significantly affect your out-of-pocket costs depending on your plan’s structure.
Evenity’s total treatment cost spans 12 monthly doses. Prolia’s cost is ongoing, with injections every six months for as long as you remain on it. Over a multi-year horizon, Prolia’s cumulative cost can exceed Evenity’s fixed course, but the two drugs serve different roles and are rarely an either/or choice for the same time period. Most patients who take Evenity will also need Prolia (or another antiresorptive) afterward, so the real cost comparison is Prolia alone versus Evenity plus Prolia in sequence.
Which One Is Right for You
If your bone density is severely low or you’ve already had fractures, the Evenity-first-then-Prolia sequence offers the fastest and largest bone density recovery available today. If your fracture risk is moderate, your cardiovascular risk is elevated, or you need a straightforward long-term option, Prolia alone is effective and well-established. The two drugs aren’t really competitors. They fill different roles, and for many patients, the best answer involves both.